- Home
- CHY vs LYEL Comparison
CHY vs LYEL Comparison
Compare CHY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$34.98
Company Overview
Basic Information| Metric | CHY | LYEL |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.3M | 745.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CHY | LYEL |
|---|---|---|
| Price | $11.72 | $34.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 128.3K | 102.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.97 | $7.65 |
| 52 Week High | $12.16 | $45.00 |
Technical Indicators
Market Signals| Indicator | CHY | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 65.03 |
| Support Level | $11.54 | $32.01 |
| Resistance Level | $11.40 | $45.00 |
| Average True Range (ATR) | 0.13 | 3.42 |
| MACD | 0.04 | 0.29 |
| Stochastic Oscillator | 84.75 | 48.14 |
Price Performance
Historical Comparison CHY
LYEL
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.